Alternatives to Retatrutide if that GLP is taken off the Market which research is demonstrating will outperform Reta

The biggest caution is that these numbers come from different trials, populations, doses, durations, and statistical methods, so they should not be treated as true head-to-head rankings unless the drugs were tested directly against each other.

Semaglutide — the GLP-1 benchmark

Semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks in the landmark STEP 1 obesity trial.

Its importance isn’t that it has the highest weight-loss percentage anymore; it’s that semaglutide established GLP-1 therapy as a major obesity-treatment platform.

Positioning:
SEMAGLUTIDE → FOUNDATION
Appetite control • satiety • established GLP-1 therapy

Tirzepatide — the established next step

Tirzepatide activates both GIP and GLP-1 receptors.

Most importantly, it has actually been compared directly with semaglutide. In a randomized obesity trial, average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide.

That gives us much stronger evidence that adding GIP receptor activity can meaningfully increase efficacy.

Positioning:
TIRZEPATIDE → DUAL POWER
GIP + GLP-1 • stronger established weight-loss efficacy

Retatrutide — currently setting the bar

Retatrutide adds a third receptor:

GIP + GLP-1 + glucagon

In Phase 3 TRIUMPH-1, the 12 mg dose produced 28.3% average weight loss at 80 weeks, while participants with baseline BMI ≥35 in an extension averaged approximately 30.3% at 104 weeks.

Lilly has also reported successful additional Phase 3 trials and says it intends to submit retatrutide to the FDA in Q1 2027.

Positioning:
RETATRUTIDE → TRIPLE AGONIST
GIP + GLP-1 + glucagon • highest late-stage weight-loss signal so far

UBT251 — perhaps the closest direct challenger

UBT251 uses the same three-receptor strategy:

GLP-1 + GIP + glucagon

In its Chinese Phase 2 obesity study, it produced up to 19.7% mean weight loss after only 24 weeks.

The short duration is what makes that number so interesting. We do not yet know whether the curve will continue toward or beyond retatrutide levels.

Positioning:
UBT251 → NEXT TRIPLE THREAT

At this point, this may be the compound I’d watch most closely if your specific question is, “What could eventually beat retatrutide?”

Enicepatide / CT-388 — surprisingly strong dual agonist

Despite targeting only:

GLP-1 + GIP

Roche reported 22.5% placebo-adjusted weight loss at 48 weeks at the highest dose tested, and importantly, the weight-loss curve had not plateaued.

That’s a very strong Phase 2 signal.

Positioning:
ENICEPATIDE → HIGH-EFFICACY DUAL

It becomes even more interesting when combined with an amylin analog.

Petrelintide — the amylin approach

Petrelintide takes a different route by mimicking amylin, a hormone involved in satiety.

As monotherapy it produced up to 10.7% mean weight reduction at 42 weeks, so by itself it currently doesn’t look like a retatrutide replacement.

Where it becomes more compelling is as a combination partner with enicepatide.

That combination essentially creates:

GLP-1 + GIP + amylin

instead of retatrutide’s:

GLP-1 + GIP + glucagon

That could become an important battle between two different three-pathway approaches.

Zenagamtide / Amycretin — GLP-1 + amylin in one molecule

Novo Nordisk’s zenagamtide combines GLP-1 and amylin receptor agonism in a single peptide.

In adults with type 2 diabetes, the highest studied dose produced up to 14.6% weight loss at 36 weeks, and Novo Nordisk is advancing the program into Phase 3.

Because people with diabetes often lose less weight in obesity-drug trials than people without diabetes, its obesity Phase 3 results will be particularly important.

Positioning:
ZENAGAMTIDE → GLP-1 + AMYLIN

Survodutide — a different glucagon strategy

Survodutide combines:

GLP-1 + glucagon

rather than adding GIP.

Phase 3 SYNCHRONIZE-1 reported substantial weight reduction over 76 weeks, but its current obesity efficacy does not appear competitive with the highest-dose retatrutide results.

Its long-term value may be broader than simple scale weight, particularly because glucagon biology is also being investigated for effects on energy expenditure and metabolic liver disease.

Positioning:
SURVODUTIDE → METABOLIC / GLUCAGON PATHWAY

The evolution is becoming pretty clear

You can think of the field like this:

SEMAGLUTIDE
GLP-1
⬇
TIRZEPATIDE
GLP-1 + GIP
⬇
RETATRUTIDE / UBT251
GLP-1 + GIP + glucagon

Meanwhile, another branch is developing:

AMYLIN
⬇
PETRELINTIDE
⬇
ZENAGAMTIDE — GLP-1 + amylin
⬇
PETRELINTIDE + ENICEPATIDE — amylin + GLP-1 + GIP

That amylin-versus-glucagon pathway competition may be one of the biggest stories in obesity-drug development over the next few years.

Current research ranking for weight-loss potential

Based on the evidence available today, rather than assuming future success:

1. Retatrutide — ~28.3% at 80 weeks
Current late-stage benchmark.

2. UBT251 — 19.7% at only 24 weeks
Potentially the most exciting direct challenger, but much earlier-stage.

3. Enicepatide — 22.5% placebo-adjusted at 48 weeks
One of the strongest emerging dual agonists.

4. Tirzepatide — ~20%+
The strongest established, approved benchmark in this comparison.

5. Petrelintide + enicepatide
Potential could be substantial, but we need mature combination data.

6. Zenagamtide
Very promising mechanistically, with Phase 3 needed to determine its ceiling.

7. Semaglutide — ~15%
Extremely important clinically, but newer multi-receptor agents have raised the efficacy ceiling.

8. Survodutide
Currently more compelling as a broader metabolic/glucagon drug than as a candidate to beat retatrutide on raw weight loss.

One correction to the original premise is important: retatrutide has not been “taken off the market.” It isn’t commercially approved yet. Lilly’s current plan is to seek FDA approval beginning in Q1 2027.

For a Command Fitness graphic, I’d title this:

BEYOND GLP-1: THE NEXT GENERATION OF WEIGHT-LOSS PEPTIDE RESEARCH

Semaglutide → Tirzepatide → Retatrutide → What’s Next?

Then spotlight UBT251, enicepatide, zenagamtide, petrelintide combinations, and survodutide as the emerging contenders rather than saying any has already proven it can outperform retatrutide.